These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 9260237

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Experience with deflazacort in children and adolescents after renal transplantation.
    Schärer K, Feneberg R, Klaus G, Paschen C, Wüster C, Mehls O, Schaefer F.
    Pediatr Nephrol; 2000 Jun; 14(6):457-63. PubMed ID: 10872183
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.
    Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D.
    Lupus; 2018 May; 27(6):890-898. PubMed ID: 29320974
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM.
    Neurology; 2016 Nov 15; 87(20):2123-2131. PubMed ID: 27566742
    [Abstract] [Full Text] [Related]

  • 9. Deflazacort induced stronger immunosuppression than expected.
    Gonzalez-Castañeda RE, Castellanos-Alvarado EA, Flores-Marquez MR, Gonzalez-Perez O, Luquin S, Garcia-Estrada J, Ramos-Remus C.
    Clin Rheumatol; 2007 Jun 15; 26(6):935-40. PubMed ID: 16738843
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
    Scudeletti M, Puppo F, Lanza L, Mantovani L, Bosco O, Iudice A, Imbimbo B, Indiveri F.
    Eur J Clin Pharmacol; 1993 Jun 15; 45 Suppl 1():S29-34. PubMed ID: 8313931
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Potency ratio--a brief synopsis.
    Avioli LV.
    Br J Rheumatol; 1993 May 15; 32 Suppl 2():24-6. PubMed ID: 8495276
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
    Loftus J, Allen R, Hesp R, David J, Reid DM, Wright DJ, Green JR, Reeve J, Ansell BM, Woo PM.
    Pediatrics; 1991 Sep 15; 88(3):428-36. PubMed ID: 1881719
    [Abstract] [Full Text] [Related]

  • 14. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
    Campbell C, Jacob P.
    BMC Neurol; 2003 Sep 08; 3():7. PubMed ID: 12962544
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Study of lymphocyte subpopulations in chronic autoimmune inflammatory rheumatic diseases. II. Polymyalgia rheumatica: behaviour of lymphocyte subpopulations during treatment with two different corticosteroids].
    Coaccioli S, Pinoca F, Giuliani M, Sabatini C, Puxeddu A.
    Minerva Med; 2005 Oct 08; 96(5):379-87. PubMed ID: 16227953
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Deflazacort in comparison to other steroids for nephrotic syndrome.
    Jat KR, Khairwa A.
    Indian J Nephrol; 2012 Jul 08; 22(4):239-45. PubMed ID: 23162265
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.